

Date: 11th January 2022

To
Corporate Relationship Department
BSE Limited
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai- 400 001.

Dear Sir's/ Madam,

Sub: Outcome - Proposal for Acquisition of Compulsory Convertible Preference Shares (CCPS) in 'Karkinos Healthcare Private Limited'

Ref: Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Scrip Code: 530951; Stock Symbol: RAMINFO

With reference to the above cited subject, this is to inform that the Board of Directors in its meeting held on 10th January 2022 at 05.30 PM had resolved to subscribe to 50 units of Compulsory Convertible Preference Shares of KARKINOS HEALTHCARE PRIVATE LIMITED (CIN:U93090MH2020PTC342527) which are being offered at Face Value INR 10/- and premium of INR 2,24,990/- amounting to INR2,25,000/- each.

Th relevant details of the transaction are enclosed as **Annexure-A**.

This disclosure is being made pursuant to Regulation 30(6) of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours Sincerely,

For **RAMINFO LIMITED**

N. Dhruv Raj
Company Secretary
ACS 64126

ANNEXURE - A

| S.No. | PARTICULARS | DETAILS |
|-------|---|---|
| A | Name of the target entity, details in brief such as size, turnover etc.; | <p>Karkinos Healthcare Private Limited, (KH) is a private company incorporated on 24/07/2020 having CIN:U93090MH2020PTC342527.</p> <p>Karkinos Healthcare Private Ltd (KH), founded in July 2020, is technology driven, oncology focused, managed health care platform. Our mission is to ensure no person is deprived of quality care either by lack of access or affordability. KH has been founded by Mr. R Venkataramanan, former Managing Trustee of the Tata Trusts (ex-board member of Tata Memorial Hospital, Tata Medical Centre Trust; Tata Centres for cancer care).</p> <p>A strong clinician team is led by Dr Moni Abraham K. (ex Director CCRC, Narayana Health, visiting professor Roswell Park Cancer Institute, NYU) and Dr. R. Sankaranarayanan (former Chief of Cancer Screening Group, Early Detection & Prevention Section and Special Advisor on Cancer Control at the International Agency for Research on Cancer, WHO).</p> <p>Karkinos is backed by the Tata Group, Mr. Ratan Tata, Rakuten Medical Inc, a leading global biotech in oncology and several prominent institutions and individuals in India and abroad. Karkinos is proud to collaborate with Tata Memorial Hospital, UK's Guys and St Thomas NHS Foundation Trust and has several research collaborations with leading academic institutions in the United States to ensure we are at the frontier of oncology treatment and care. The company also has several professionals of eminence in cancer care as part of its Global Scientific Advisory Board.</p> <p>The Turnover of KH is INR 0.36 lakhs as on 31st March 2021.</p> |
| B | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at | <p align="center">NO</p> |

| | | |
|---|---|---|
| | “arm’s length” | |
| C | Industry to which the entity being acquired belongs; | Healthcare Technology & Data Analytics |
| D | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | RAMINFO intend collaborate closely with Karkinos to strengthen Healthcare vertical by leveraging Karkinos hybrid “hub and spoke” _model, with owned specialized centers of clinical excellence and a distributed network of partners for last mile reach and delivery of care. A robust technology backbone, with clinical decision support systems, ensures high quality service delivery that focuses on the patient’s well-being. |
| E | Brief details of any governmental or regulatory approvals required for the acquisition; | NO |
| F | Indicative time period for completion of the acquisition; | 28 th February 2022. |
| G | Nature of consideration - whether cash consideration or share swap and details of the same; | Cash/Banking Channel |
| H | Cost of acquisition or the price at which the shares are acquired; | Approximately INR 112.50 Lakhs |
| I | Percentage of shareholding / control acquired and / or number of shares acquired; | Less than 1% |
| J | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | <p>Karkinos Healthcare Pvt Ltd (KH), founded in July 2020, is technology driven, oncology focused, managed health care platform.</p> <p>Mission: To ensure “no person is deprived of quality care either by lack of access or affordability”</p> <p>KH offers medically validated risk assessment tools and screening services for 5 common forms of cancer, which are the major cancer burden in India:</p> <ul style="list-style-type: none"> • Breast cancer: Clinical Breast Exam • Cervix cancer: HPV test • Oral cancer: Oral Visual Exam • Colorectal cancer: FIT • Prostate cancer: PSA <p style="text-align: center;">Date of Incorporation: 24/07/2020. Turnover of KH for last 3 years:</p> <p>FY-2020-21 (as on 31st March 2021): INR 0.36 Lakhs.</p> |